Just some of the things that happened over the las
Post# of 1418
You should see the list of the next 6 months, first of which is Q1 results coming mid May.
May 02, 2022 10:02am EDT
Todos Medical Receives New FDA Certificate of Free Sale for Tollovid® Max Strength Including 5 Day Dosing, 30 Day Dosing and 3CL Protease (3CLpro, Mpro, Nsp5) Inhibitor Claim
Apr 27, 2022 9:49am EDT
Todos Medical Initiates IRB-Waived Tollovid Market Research Study and Announces 50% Price Reduction Until May 30th, 2022
Apr 25, 2022 10:51am EDT
Todos Medical to Present at the Emerging Growth Conference
Apr 21, 2022 7:59am EDT
Todos Medical Appoints Philippe Goix as Chief Commercial Officer for Provista Diagnostics
Apr 20, 2022 8:01am EDT
Todos Medical Reports 2nd Long COVID Case Study and Launches Website for Physicians and Pediatricians to Indicate Interest in Participating in Tollovid Long COVID Clinical Study
Apr 19, 2022 7:22am EDT
Todos Medical Targets Athlete Support with Informed Sport Certification for Tollovid by LGC Group
Apr 06, 2022 8:46am EDT
Todos Medical Applauds White House Initiative on Long COVID and Announces New Tollovid® US FDA Certificate of Free Sale with Daily and Acute Dosing on the Label
Apr 04, 2022 9:11am EDT
Todos Medical Announces Positive 3CL Protease Inhibition In Vitro Data Against BA.1 and BA.2 Omicron SARS-CoV-2 Variants
Apr 01, 2022 2:17pm EDT
Update: Todos Medical Reports Fourth-Quarter and Full-Year 2021 Financial Results and Corporate Updates
Apr 01, 2022 11:29am EDT
Todos Medical Reports Fourth-Quarter and Full-Year 2021 Financial Results and Corporate Updates
Mar 31, 2022 11:17am EDT
Todos Medical Reports Case Study of Patient with Long COVID
Mar 28, 2022 8:21am EDT
Billy Blanks® Endorses Todos Medical’s Line of Tollovid® Products
Mar 17, 2022 7:00am EDT
Todos Medical to Present at the Proactive One2One Virtual Forum
Mar 16, 2022 7:00am EDT
Todos Medical Completes Acquisition of Key Assets and Intellectual Property from NLC Pharma
Mar 15, 2022 7:00am EDT
Todos Medical to Present at the Emerging Growth Conference
Mar 08, 2022 9:53am EST
Todos Medical Appoints Greg Meiselbach as Vice President of Government Affairs
Jan 27, 2022 8:23am EST
Todos Medical and NLC Pharma Announce Primary and Secondary Endpoints Met in NLC-V-01 Phase 2 Clinical Trial of Oral Antiviral 3CL Protease Inhibitor Tollovir™ in the Treatment of Hospitalized COVID-19 Patients
Jan 24, 2022 8:34am EST
Todos Medical Announces Data Lock in Tollovir Phase 2 Clinical Trial for the Treatment of Hospitalized COVID-19 Patients
Jan 19, 2022 8:00am EST
Pepperdine University Hosts the 22nd Annual Celebrity Flag Football Challenge®, Presented by Todos Medical’s Tollovid®
Jan 18, 2022 10:52am EST
Todos Medical Releases Videos of Recent CEO Interviews with Fox Business, NewsMax and Black News Channel on COVID Testing & Treatment Strategies
Jan 12, 2022 9:56am EST
Todos Medical to Announce Topline Results from Tollovir™ Phase 2 Clinical Trial from the Treatment of Hospitalized COVID-19 Patients on January 27th, 2022
Jan 10, 2022 2:06pm EST
Todos Medical CEO to Appear on Fox Business to Talk COVID Testing & Tollovir on Tuesday, January 11, 2022 and is Presenting at Biotech Showcase 2022
Jan 05, 2022 6:04pm EST
Todos Medical CEO Provides Letter to Shareholders
Jan 03, 2022 8:30am EST
Todos Medical to Present at January 5, 2022 Emerging Growth Conference
Dec 27, 2021 9:01am EST
Todos Medical Records Record Weekly COVID PCR Testing Volumes at Provista
Dec 23, 2021 7:37am EST
Todos Medical CEO to Appear on Yahoo Finance Live! at 12:10PM EST with Akiko Fujita to Talk Pfizer’s Paxlovid Approval, Tollovir™ Phase 2 & COVID Testing
Dec 22, 2021 9:56am EST
Todos Medical Announces New cPass Neutralizing Antibody Testing Reference Lab Agreement for CLIA/CAP Lab Provista with Physician Group in 40 States
Dec 20, 2021 7:30am EST
Todos Medical Appoints Valentino Smith, MBA as Vice President of Marketing
Dec 17, 2021 8:51am EST
Todos Medical Announces “Test & Tollovid®” Holiday Package for Atlanta Area at Provista Diagnostics
Dec 16, 2021 12:25pm EST
Todos Medical to Host Key Opinion Leader Webinar Entitled Tollovir™: a Potential Treatment for Covid-19
Dec 13, 2021 7:30am EST
Todos Medical Enters 90-Day Extension of Agreement with Convertible Note Holders on Moratorium on Conversions of Convertible Notes
Dec 10, 2021 12:29pm EST
Todos Medical Interview and Presentation on Benzinga's All Access Conference Live December 14th at 10:20 AM EST
Dec 07, 2021 9:19am EST
Todos Medical Announces 2 New COVID-19 PCR Testing Reference Lab Agreements for CLIA/CAP Lab Provista Diagnostics
Dec 06, 2021 3:14pm EST
Todos Medical to Present at Upcoming Emerging Growth Conference
Dec 02, 2021 6:00am EST
Todos Medical Announces All 31 Patients Enrolled to Date in Tollovir® Phase 2 Clinical Trial in Hospitalized COVID-19 Patients Have Completed Study Participation
Dec 01, 2021 4:05pm EST
Todos Medical to Host Business Update Conference Call on December 2nd at 4:30 PM EST
Nov 30, 2021 8:38am EST
Todos Medical Confirms SARS-CoV-2 PCR Test Kits Used at CLIA/CAP Lab Provista Diagnostics Detect Omicron Variant
Nov 29, 2021 9:08am EST
Todos Medical Enters into Binding Agreement to Acquire All 3CL Protease Biology-Related Assets and Intellectual Property from NLC Pharma
Nov 24, 2021 2:00am EST
Todos Medical Announces Exclusive License & Distribution Agreement with T-Cell Protect Hellas S.A. for Tollovid® Products Covering 30 Countries in Europe
Nov 22, 2021 8:26am EST
Todos Medical Receives Purchase Order for 50,000 Bottles of Tollovid Daily from Its European Distribution Partner T-Cell Protect Hellas S.A for Initial Market Launch in Greece
Nov 19, 2021 7:30am EST
Todos Medical Announces Completion of Enrollment for COVID-19 Oral Antiviral 3CLPro (Mpro) Inhibitor Tollovir Phase 2 Clinical Trial Interim Analysis in Severe and Critical Hospitalized Patients
Nov 18, 2021 6:00am EST
Todos Medical Announces Tollovid® Products Exclusive License & Distribution Agreement with T-Cell Protect Hellas S.A. Covering 30 Countries in Europe
Nov 17, 2021 6:02pm EST
Todos Medical Announces Addition of Semi-Quantitative Titer Claims to the Emergency Use Authorization for the cPass Neutralizing Antibody Test
Nov 16, 2021 1:18pm EST
Update: Todos Medical Reports Third Quarter 2021 Business and Financial Results
Nov 16, 2021 9:55am EST
Todos Medical’s Provista Laboratory to Boost Top Line Through New Atlanta-based Reference Lab Agreement for COVID PCR, cPass Neutralizing Antibody & Respiratory Pathogen Panel Tests
Nov 15, 2021 7:18pm EST
Todos Medical Reports Third Quarter 2021 Business and Financial Results
Nov 02, 2021 9:05am EDT
Todos Medical Sees Significant Ramp Up in COVID PCR Testing Volume at Its Provista CLIA/CAP Lab with New Automation in Place
Nov 01, 2021 7:35am EDT
Todos Medical Announces 2nd Clinical Trial Site for Tollovir Phase 2 Clinical Trial for the Treatment of Hospitalized COVID-19 Patients